upsid cautiou guid driven
multipl one-off core still messi
look good paper read fine print
slash outlook last qtr mani saw kitchen sink
anticip upsid result inde report sale well-ahead
estim consensu howev benefit number
time stock licens revenu pull-forward underli product
revenu best in-lin result top-line beat favor product mix
cost control wont continu gross oper margin also came well-ahead
respect lead big adj ep beat vs street
exclud one-tim benefit look like miss
note sever unexpect tailwind sale growth includ
collabor revenu tie ivd in-vitro diagnost co-develop
agreement incl qiagen around seq consum stock revenu
larger-than-expect number novaseq shipment tie uk biobank even allow
flexibl time instrument shipment bolu ivd co-develop
revenu surpris previous built expect underli
revenu like rang
chang prior view lack visibl limit control
downgrad under-perform follow pre-announce base number
factor lack visibl revenu time lack control custom demand
clear catalyst drive meaning reacceler beyond easi comp
yesterday result serv reinforc view acknowledg larg popseq
studi nation health servic uk biobank allofu could meaning
contributor surpris upsid beyond continu see
downsid risk big ticket deal also lead volatil result
depend hand govt-run project time increas uncertainti
time valuat alreadi indic expect solid rebound
remain under-perform share look updat ilmn
product pipelin project pace shipments/util reassess
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit technolog
market posit overal genom
market see near-term risk tie execut
visibl custom time demand
pend acquisit macro
competit risk
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim in-lin
year averag forward multipl consid justifi given near-term question
certain pocket busi relat execut
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit relat
integr issu grow concern data privaci slower-than-expect
uptak new product
upsid risk po strong recoveri instrument placement overal
sequenc demand new product cycl stabilization/recoveri direct-to-
consum dtc market increas spend high-throughput custom better
clinic reimbursement/market penetr acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
